Literature DB >> 9349557

Regulation of spontaneous activity of the delta-opioid receptor: studies of inverse agonism in intact cells.

M Merkouris1, I Mullaney, Z Georgoussi, G Milligan.   

Abstract

Adenylyl cyclase activity was measured following labelling of the cellular ATP pool with [3H]adenine in intact Rat-1 fibroblasts that had been stably transfected to express the murine delta-opioid receptor (clone D2). Basal [3H]cyclic AMP accumulation was low and was increased substantially by the addition of the diterpene forskolin. The synthetic enkephalin D-Ala2,D-Leu5 enkephalin (DADLE) produced strong inhibition of forskolin-amplified [3H]cyclic AMP production, whereas the delta-opioid ligand ICI174864 augmented forskolin-amplified adenylyl cyclase activity. Naloxone was unable to mimic the effects of ICI174864, and coincubation of the cells with these two ligands attenuated the effect of ICI174864. The EC50 (9.4 +/- 0.6 x 10(-8) M) for ICI174864 augmentation of forskolin-stimulated adenylyl cyclase was equal to its estimated Ki. Pertussis toxin pretreatment of clone D2 cells prevented both this effect of ICI174864 and the inhibition produced by DADLE. Use of a Cytosensor microphysiometer demonstrated that treatment of clone D2 cells with DADLE increased and that with ICI174864 decreased the basal rate of cellular proton extrusion. By using these two distinct experimental strategies, ICI174864 was shown to function in a manner anticipated for an inverse agonist, demonstrating that such effects can be observed in intact cells and are not restricted to assays performed on membrane preparations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9349557     DOI: 10.1046/j.1471-4159.1997.69052115.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

1.  Detection of receptor ligands by monitoring selective stabilization of a Renilla luciferase-tagged, constitutively active mutant, G-protein-coupled receptor.

Authors:  D Ramsay; N Bevan; S Rees; G Milligan
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Analysis of agonist function at fusion proteins between the IP prostanoid receptor and cognate, unnatural and chimaeric G-proteins.

Authors:  C W Fong; G Milligan
Journal:  Biochem J       Date:  1999-09-01       Impact factor: 3.857

3.  Structural features determining differential receptor regulation of neuronal Ca channels.

Authors:  A A Simen; R J Miller
Journal:  J Neurosci       Date:  1998-05-15       Impact factor: 6.167

4.  Ligand regulation of green fluorescent protein-tagged forms of the human beta(1)- and beta(2)-adrenoceptors; comparisons with the unmodified receptors.

Authors:  A J McLean; G Milligan
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

5.  Opiate antagonist prevents μ- and δ-opiate receptor dimerization to facilitate ability of agonist to control ethanol-altered natural killer cell functions and mammary tumor growth.

Authors:  Dipak K Sarkar; Amitabha Sengupta; Changqing Zhang; Nadka Boyadjieva; Sengottuvelan Murugan
Journal:  J Biol Chem       Date:  2012-03-27       Impact factor: 5.157

6.  Effects of sodium on agonist efficacy for G-protein activation in mu-opioid receptor-transfected CHO cells and rat thalamus.

Authors:  D E Selley; C C Cao; Q Liu; S R Childers
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

7.  Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists.

Authors:  C L Neilan; H Akil; J H Woods; J R Traynor
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

8.  Regulation of the avidity of ternary complexes containing the human 5-HT(1A) receptor by mutation of a receptor contact site on the interacting G protein alpha subunit.

Authors:  Philip J Welsby; I Craig Carr; Graeme Wilkinson; Graeme Milligan
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

9.  In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist-neurokinin 1 receptor antagonist chimera.

Authors:  Karel Guillemyn; Patrycja Kleczkowska; Alexandre Novoa; Bart Vandormael; Isabelle Van den Eynde; Piotr Kosson; Muhammad Faheem Asim; Peter W Schiller; Mariana Spetea; Andrzej W Lipkowski; Dirk Tourwé; Steven Ballet
Journal:  Mol Brain       Date:  2012-01-30       Impact factor: 4.041

10.  Enhanced spontaneous activity of the mu opioid receptor by cysteine mutations: characterization of a tool for inverse agonist screening.

Authors:  Karl Brillet; Brigitte L Kieffer; Dominique Massotte
Journal:  BMC Pharmacol       Date:  2003-12-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.